Table 1

Clinical pathological findings in kidney transplant recipients

Age, years

Gender

Kidney disease

Transplant type

Time, mos

Sirolimus trough levels, mean(range), ng/ml

Other immuno-suppressants

Clinical radiological presentation

Biopsy type

Pathological findings


1*

49

M**

DM1

K/Cad

11

11.7(6.2-18.7)

C/P

Bilateral mass-like consolidations

EB

ND


2

25

F

DM1

K/Cad

20

C/MY/D

Patchy bilateral consolidations

EB

BCLPD


3

71

M

PCKD

K/Cad

36

C/D

Mediastinal lymphadenopathy

EB LNB

DLBCL


4

58

F

DM2

K/Cad

5

8.8(4.0-17.1)

C/P

Respiratory failure Diffuse ground glass opacities

EB THB

Hemorrhage


5

47

F

HTN

K/Cad

210

C/MY/P

Respiratory failure, loculated pneumonia

EB

Necrosis

Fibrin


6

72

M

DM2

K/Cad

20

4.8(2.0-8.2)

C/P

Spiculated lung lesion

NB

SQC


7

77

M

K/Cad

116

C/D

Pulmonary nodule

EB

SQC


8

71

M

pANCA

K/Cad

10

15.1

C/P

Right lower lobe mass

EB

ND


Diffuse ground glass opacities


9

48

F

NA

K/Cad

32

NA

MY/P

Left lower lobe nodule

EB

Necrosis

Fibrin


10

39

M

GN

K/Cad

80

10.2(8.1-11.8)

C/P

Respiratory failure, diffuse ground glass opacities with crazy paving pattern

THB

EB

Hemorrhage PAP

OP


11

45

F

NA

K/Cad, LR

345

C/P

Collapsed lung, pneumonia

EB

OP


12

58

F

HTN

K/Cad

24

19.7

C/P

Respiratory failure, diffuse ground glass opacities

EB THB

Hemorrhage


13

44

F

DM2

K/LR

36

5.3(3.2-6.9)

C/P

Mediastinal lymphadenopathy, patchy ground glass opacities

EB

ND


14

46

M

WG

K/LR

175

C/MY/P

Diffuse ground glass opacities, lung nodules

EB

NB

Hemorrhage

Capillaritis


15

49

F

DM

K

73

8.1(4.3-11.6)

C/P

Bilateral ground glass opacification with right lower lobe consolidation

EB

OP


16

34

F

DM1

KP/Cad

19

4.2(2.4-6.7)

C/P

Respiratory failure, diffuse ground glass opacities

THB

DAD Hemorrhage


17

43

M

DM1

KP

41

4.4

C/P

Nodular right lower lobe infiltrate

EB

ND


18

69

M

DM2

K/LU

4

11.0(5.0-14.9)

C/P

Bilateral lung nodules and mediastinal lymphadenopathy

NB

BCLPD


19

71

M

IgA

K/LR

114

C/P

Dyspnea, diffuse ground glass opacities

EB

PAP


20

60

M

GN

K/LR

89

C/MY/D

Lung nodule

EB

ND


21

65

M

K/LR

41

6.8(2.8-12.0)

MA/P

Bilateral hypermetabolic lung nodules

THB

PJ granulomas


22

60

M

GN

K/LR

66

C/P

Lung mass

THB

ADC


23

52

M

DM1

KP/Cad

73

C/P

Lung mass

EB

SQC


24

34

M

GN

K/Cad

38

10.2(6.1-14.3)

C/P

Bilateral ground glass opacities

Loculated right sided pleural effusion

EB

Fibrin

Necrosis


25

36

F

NA

K

180

C/P

Bilateral lung nodules, lymphadenopathy

THB NB

LYG


26

62

M

IN

K/LR

115

C/P

Lung mass

NB

ADC


27

53

M

PCKD

K/LU

61

2.0

MA/P

Lung nodule, pleural effusion

EB

ND


28

32

M

CR

K/LU

220

8.6(4.4-13.2)

C/MA/P

Dyspnea, patchy ground glass opacities

EB

OP


(*) - the cases are arranged in chronological order; (**)-M male; F female; DM diabetes mellitus; PCKD polycystic kidney disease; HTN hypertension; p-ANCA p-ANCA vasculitis; GN glomerulonephritis; WG Wegner's granulomatosis; IgA IgA nephropathy; IN interstitial nephritis; CR chronic reflux; K kidney transplant; KP kidney and pancreas transplant; Cad cadaveric kidney; LR living related kidney; LU living unrelated kidney; EB endobronchial biopsy; THB thoracoscopic biopsy; NB needle biopsy; LNB lymph node biopsy; C cyclosporine; P prednisone; D dexamethasone; MY mycophenolate mofetil; MA mycophenolic acid; ND not diagnostic; SQC squamous cell carcinoma; ADC adenocarcinoma; BCLPD B-cell lymphoproliferative disorder; DLBCL diffuse large B-cell lymphoma; LYG lymphomatoid granulomatosis; OP organizing pneumonia; DAD diffuse alveolar damage; PJ Pneumocystis jiroveci; PAP pulmonary alveolar proteinosis; NA not available

Kirby et al. Diagnostic Pathology 2012 7:25   doi:10.1186/1746-1596-7-25

Open Data